138 related articles for article (PubMed ID: 24947326)
1. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells.
Montavon G; Jauquier N; Coulon A; Peuchmaur M; Flahaut M; Bourloud KB; Yan P; Delattre O; Sommer L; Joseph JM; Janoueix-Lerosey I; Gross N; Mühlethaler-Mottet A
Oncotarget; 2014 Jun; 5(12):4452-66. PubMed ID: 24947326
[TBL] [Abstract][Full Text] [Related]
2. ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
Huang M; Fang W; Farrel A; Li L; Chronopoulos A; Nasholm N; Cheng B; Zheng T; Yoda H; Barata MJ; Porras T; Miller ML; Zhen Q; Ghiglieri L; McHenry L; Wang L; Asgharzadeh S; Park J; Gustafson WC; Matthay KK; Maris JM; Weiss WA
Cell Rep; 2024 Mar; 43(3):113927. PubMed ID: 38451815
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.
Jamin Y; Glass L; Hallsworth A; George R; Koh DM; Pearson AD; Chesler L; Robinson SP
PLoS One; 2014; 9(3):e92886. PubMed ID: 24667968
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase (alk), a neuroblastoma associated gene, is expressed in neural crest domains during embryonic development of Xenopus.
Moreno MM; Barrell WB; Godwin A; Guille M; Liu KJ
Gene Expr Patterns; 2021 Jun; 40():119183. PubMed ID: 34020009
[TBL] [Abstract][Full Text] [Related]
5. Identification of
Aktaş TÇ; Kızmazoğlu D; Aktaş S; Gökbayrak ÖE; Serinan E; Erol A; Altun Z; Yuan H; Olgun HN
Technol Cancer Res Treat; 2023; 22():15330338231211138. PubMed ID: 37964559
[TBL] [Abstract][Full Text] [Related]
6. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.
Borenäs M; Umapathy G; Lind DE; Lai WY; Guan J; Johansson J; Jennische E; Schmidt A; Kurhe Y; Gabre JL; Aniszewska A; Strömberg A; Bemark M; Hall MN; Eynden JVD; Hallberg B; Palmer RH
Proc Natl Acad Sci U S A; 2024 Jan; 121(1):e2315242121. PubMed ID: 38154064
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features.
Phan TDA; Nguyen TQ; To NT; Thanh TL; Ngo DQ
J Pathol Transl Med; 2024 Jan; 58(1):29-34. PubMed ID: 38229432
[TBL] [Abstract][Full Text] [Related]
8. Patient-associated mutations in Drosophila Alk perturb neuronal differentiation and promote survival.
Pfeifer K; Wolfstetter G; Anthonydhason V; Masudi T; Arefin B; Bemark M; Mendoza-Garcia P; Palmer RH
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35972154
[TBL] [Abstract][Full Text] [Related]
9. IGF1R Contributes to Cell Proliferation in
Guan J; Borenäs M; Xiong J; Lai WY; Palmer RH; Hallberg B
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686528
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma differentiation in vivo excludes cranial tumors.
Treffy RW; Rajan SG; Jiang X; Nacke LM; Malkana UA; Naiche LA; Bergey DE; Santana D; Rajagopalan V; Kitajewski JK; O'Bryan JP; Saxena A
Dev Cell; 2021 Oct; 56(19):2752-2764.e6. PubMed ID: 34610330
[TBL] [Abstract][Full Text] [Related]
11. A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma.
Perri P; Ponzoni M; Corrias MV; Ceccherini I; Candiani S; Bachetti T
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771690
[TBL] [Abstract][Full Text] [Related]
12. Human iPSC modeling recapitulates
Van Haver S; Fan Y; Bekaert SL; Everaert C; Van Loocke W; Zanzani V; Deschildre J; Maestre IF; Amaro A; Vermeirssen V; De Preter K; Zhou T; Kentsis A; Studer L; Speleman F; Roberts SS
iScience; 2024 Jan; 27(1):108096. PubMed ID: 38222111
[TBL] [Abstract][Full Text] [Related]
13. A Germline Point Mutation in the MYC-FBW7 Phosphodegron Initiates Hematopoietic Malignancies.
Freie B; Carroll PA; Varnum-Finney BJ; Ramani V; Bernstein I; Eisenman RN
bioRxiv; 2023 Oct; ():. PubMed ID: 37961183
[TBL] [Abstract][Full Text] [Related]
14. Tumor-suppressive disruption of cancer subtype-associated super enhancer circuits by small molecule treatment.
Koeniger A; Polo P; Brichkina A; Finkernagel F; Visekruna A; Nist A; Stiewe T; Daude M; Diederich WE; Gress TM; Adhikary T; Lauth M
NAR Cancer; 2023 Mar; 5(1):zcad007. PubMed ID: 36755960
[TBL] [Abstract][Full Text] [Related]
15. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
16. Emergence of new ALK mutations at relapse of neuroblastoma.
Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
[TBL] [Abstract][Full Text] [Related]
17. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
[TBL] [Abstract][Full Text] [Related]
18. Recent insights into the biology of neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Delattre O
Int J Cancer; 2014 Nov; 135(10):2249-61. PubMed ID: 25124476
[TBL] [Abstract][Full Text] [Related]
19. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
